Intraoperative Versus CT Guided Celiac Plexus Neurolysis in Unresectable Pancreatic Cancer

Sponsor
Mansoura University (Other)
Overall Status
Completed
CT.gov ID
NCT03770247
Collaborator
(none)
76
1
2
13
5.9

Study Details

Study Description

Brief Summary

Many studies had stated that the coeliac plexus neurolysis (CPN) is a safe and effective treatment method of pain associated with pancreatic cancer. The neurolytic injectate is usually alcohol 50-100%; however, phenol >5% is also possible to use. Nowadays, there are several techniques to access the coeliac plexus (per cutaneous using fluoroscopy or computed tomographic imaging (CT), surgical and endoscopic ultrasound). However, the percutaneous computed tomography guided technique is the gold standard technique, it has multiple drawbacks as availability and cost of imaging modality, exposure to radiation and multiple complications.Surgical technique in spite of being easy, cheap but there is a controversy about its efficacy. Also there is no head to head comparison between the surgical technique and the percutaneous technique.In this study we hypothesized that intraoperative technique has the same efficacy of percutaneous celiac block technique with less complication and cost

Condition or Disease Intervention/Treatment Phase
  • Procedure: Intraoperative celiac plexus neurolysis
  • Procedure: CT guided celiac plexus neurolysis
N/A

Detailed Description

This study aimed to compare the efficacy of the surgical technique versus the per cutaneous computed tomographic guided technique of celiac plexus neurolysis for pain management in unresectable pancreatic cancer . all patients suffering from pain of pancreatic cancer with VAS≥5 undergoing laparotomy and proved to be unresectable either undergoing biopsy or bypass surgery will receive celiac plexus neurolysis either intraoperative or post operative CT guided . All patients will be managed by systemic analgesic if the block not sufficient . In this study we will give the patient the analgesic according to WHO recommendation as starting by non steroidal anti inflammatory drugs as diclofenac sodium, if it is not sufficient we will give them opioids as tramadol, and for neuropathic pain gabapentin. All drugs will be given with escalating dose . Failed block defined as change in VAS between VAS BASELINE AND ONE MONTH ≤ 3 may need to repeat the block by percutaneous technique .

Study Design

Study Type:
Interventional
Actual Enrollment :
76 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Direct Intraoperative Injection Versus Percutaneous CT Guided Celiac Plexus Neurolysis in Unresectable Pancreatic Cancer ; Randomized Controlled Study
Actual Study Start Date :
Sep 1, 2018
Actual Primary Completion Date :
Sep 1, 2019
Actual Study Completion Date :
Oct 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: intraoperative group (IOCPN group)

Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.

Procedure: Intraoperative celiac plexus neurolysis
neurolysis of celiac plexus by intraoperative techniques

Active Comparator: CT group (CTCPN group)

CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection

Procedure: CT guided celiac plexus neurolysis
Neurolysis of celiac plexus percutaneously by CT guidance

Outcome Measures

Primary Outcome Measures

  1. assesment of efficacy in pain palliation by change in VAS after one month [one month]

    change in visual analogue scale ( VAS) after one month visual analogue scale is pain scale from 0 to 10 , 0 no pain , 10 maximum pain lower VAS better than higher .a positive responce defined as decrease of VAS of equal or more than 3

Secondary Outcome Measures

  1. incidence of complication [one month]

    report the occurrence of complication as headache , diarrhea , vomiting , back pain

  2. total analgesic consumption [6 month]

    the amount of analgesic required

  3. duration of pain palliation [6 month]

    change of visual analogue scale from baseline for 6 months visual analogue scale represent pain from 0 no pain to 10 maximum pain

  4. need of other injection [6 months]

    if failure of intervention occured patient may need another intervention

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients suffering of pain from pancreatic cancer with baseline VAS≥5, scheduled for surgical assessment

  • patients proven histololgically to be unresectable

  • patients undergoing either biopsy or bypass surgery

Exclusion Criteria:
  • patient with resectable tumour will be excluded.

  • Patient with coagulopathy.

  • patient with aortic aneurysm.

  • patient with any disease contraindicating any sympathetic blockade as advanced cardiac disease .

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mansoura university , gastrointestinal surgery center Mansourah Dakahlia Egypt

Sponsors and Collaborators

  • Mansoura University

Investigators

  • Study Director: Tarek M. Shams, MD, : Professor of Anesthesia and Surgical Intensive Care
  • Principal Investigator: Mahmoud M. Elsedeiq, MSc, assistan lecturer of Anesthesia and Surgical Intensive Care
  • Study Chair: Mohamed A. Ghanim, MD, Assistant Professor of Anesthesia and Surgical Intensive Care
  • Study Chair: Ibrahim I. Abd El-basir, MD, Lecturer of Anesthesia and Surgical Intensive Care

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mansoura University
ClinicalTrials.gov Identifier:
NCT03770247
Other Study ID Numbers:
  • MD ∕ 17.08.53
First Posted:
Dec 10, 2018
Last Update Posted:
Dec 24, 2019
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 24, 2019